James C. Fang
( out of 164 reviews )

James C. Fang, MD

Languages spoken: English

Clinical Locations

Redstone Health Center

Park City
435-658-9200

Cardiovascular Center

Cardiovascular Center
Salt Lake City
801-585-7676

University of Utah Hospital

Salt Lake City
801-585-7676

  • James Chen-tson Fang, M.D., is the Chief of Cardiovascular Medicine at the University of Utah School of Medicine and Director of the Cardiovascular Service Line at University of Utah Health Care. He holds the John and June B. Hartman Presidential Endowed Chair and is Professor of Medicine at the University of Utah School of Medicine.

    Dr. Fang graduated from Duke University with a major in Mathematics and minor in Chemistry (1984) and received his medical degree from the Duke University School of Medicine (1988). He completed his internship and residency at the Johns Hopkins Hospital (1991) and was selected as an Assistant Chief of Service (Chief Resident) for the Johns Hopkins Hospital (1993). He completed his cardiovascular (1996) and heart failure/transplant fellowships (1997) at Brigham and Women’s Hospital/Harvard Medical School.

    His first faculty appointment was at the Brigham and Women’s Hospital/Harvard Medical School in 1997, where he remained until 2006. He served as Associate Professor of Medicine, Medical Director of the Heart Transplant Program as well as Program Director of the Cardiovascular Fellowship Training Program during his tenure in Boston.

    In 2006, he was recruited to University Hospitals/Case Western Reserve University School of Medicine in Cleveland as Clinical Chief of Cardiovascular Medicine/Associate Chief for Clinical Affairs, Medical Director of the Heart Failure, Transplant, and Circulatory Assist Program and Chief Medical Officer for the Harrington Heart and Vascular Institute. While in Cleveland, he also held the Spitz Master Clinician Chair at Case Western Reserve University School of Medicine, where he was a Professor of Medicine.

    In 2013, he assumed the role of Chief of Cardiovascular Medicine at the University of Utah and Executive Director of the UU Health’s Cardiovascular Service Line. Dr. Fang’s role at the University of Utah includes leading efforts to ensure the institution is recognized as a premier clinical, educational, and research institution for cardiovascular disease. He continues to develop highly skilled multidisciplinary teams that provide comprehensive, personalized and cost-effective care, and oversees the research, education and clinical care programs of the Cardiovascular Division.


    Dr. Fang is a highly regarded clinician, teacher, mentor and researcher. He is the author of more than 175 original articles, editorials, and book chapters and has lectured nationally and internationally. He has been part of a number of important cardiovascular research groups and collaborations and has special interest in heart failure with preserved ejection fraction, advanced heart failure, coronary artery vasculopathy of the transplanted heart, and the cardiorenal syndrome. He has led several position statements for the Heart Failure Society of America as well as the International Society for Heart and Lung Transplantation. He currently serves on the ACC/AHA Heart Failure Guideline Committee and on the Board of Directors of the Heart Failure Society of America. He was elected to the Association of University Cardiologists in 2013 and is a member of the Executive Committee of the Association of Professors of Cardiology.

    Specialties

    Patient Rating

    4.9 /5
    ( out of 164 reviews )

    The patient rating score is an average of all responses on our patient experience survey. The rating averages scores for all questions about care from our providers.

    The scale on which responses are measured is 1 to 5 with 5 being the best score.

    Patient Comments

    Patient comments are gathered from our patient experience survey and displayed in their entirety.
    Patients are de-identified for confidentiality and patient privacy.

    October 30, 2024
    REDSTONE HEALTH CENTER

    Dr. Fang is an excellent cardiologist who has superb bedside manner.

    October 29, 2024
    REDSTONE HEALTH CENTER

    Super great guy. Very professional!

    October 16, 2024
    REDSTONE HEALTH CENTER

    Dr Fang was extremely gentle. explaining everything. Listened to my questions and concerns. I highly recommend him.

    September 26, 2024
    REDSTONE HEALTH CENTER

    Dr. Fang and Dr. Welt are terrific. Can't say enough good things about them

    September 11, 2024
    REDSTONE HEALTH CENTER

    A really good Doctor

    July 27, 2024
    REDSTONE HEALTH CENTER

    Dr Fang and his assistant listened to my questions and concerns and answered substantively and professionally.

    July 18, 2024
    UH HOSPITALS AND CLINICS

    Very good doctor.

    July 10, 2024
    REDSTONE HEALTH CENTER

    Easy to talk to. Easy to understand. Kind. Helpful. Caring.

    July 09, 2024
    REDSTONE HEALTH CENTER

    His bedside manner is exceptional His caring is warm and friendly

    See More Patient Comments

  • James Chen-tson Fang, M.D., is the Chief of Cardiovascular Medicine at the University of Utah School of Medicine and Director of the Cardiovascular Service Line at University of Utah Health Care. He holds the John and June B. Hartman Presidential Endowed Chair and is Professor of Medicine at the University of Utah School of Medicine.

    Dr. Fang graduated from Duke University with a major in Mathematics and minor in Chemistry (1984) and received his medical degree from the Duke University School of Medicine (1988). He completed his internship and residency at the Johns Hopkins Hospital (1991) and was selected as an Assistant Chief of Service (Chief Resident) for the Johns Hopkins Hospital (1993). He completed his cardiovascular (1996) and heart failure/transplant fellowships (1997) at Brigham and Women’s Hospital/Harvard Medical School.

    His first faculty appointment was at the Brigham and Women’s Hospital/Harvard Medical School in 1997, where he remained until 2006. He served as Associate Professor of Medicine, Medical Director of the Heart Transplant Program as well as Program Director of the Cardiovascular Fellowship Training Program during his tenure in Boston.

    In 2006, he was recruited to University Hospitals/Case Western Reserve University School of Medicine in Cleveland as Clinical Chief of Cardiovascular Medicine/Associate Chief for Clinical Affairs, Medical Director of the Heart Failure, Transplant, and Circulatory Assist Program and Chief Medical Officer for the Harrington Heart and Vascular Institute. While in Cleveland, he also held the Spitz Master Clinician Chair at Case Western Reserve University School of Medicine, where he was a Professor of Medicine.

    In 2013, he assumed the role of Chief of Cardiovascular Medicine at the University of Utah and Executive Director of the UU Health’s Cardiovascular Service Line. Dr. Fang’s role at the University of Utah includes leading efforts to ensure the institution is recognized as a premier clinical, educational, and research institution for cardiovascular disease. He continues to develop highly skilled multidisciplinary teams that provide comprehensive, personalized and cost-effective care, and oversees the research, education and clinical care programs of the Cardiovascular Division.


    Dr. Fang is a highly regarded clinician, teacher, mentor and researcher. He is the author of more than 175 original articles, editorials, and book chapters and has lectured nationally and internationally. He has been part of a number of important cardiovascular research groups and collaborations and has special interest in heart failure with preserved ejection fraction, advanced heart failure, coronary artery vasculopathy of the transplanted heart, and the cardiorenal syndrome. He has led several position statements for the Heart Failure Society of America as well as the International Society for Heart and Lung Transplantation. He currently serves on the ACC/AHA Heart Failure Guideline Committee and on the Board of Directors of the Heart Failure Society of America. He was elected to the Association of University Cardiologists in 2013 and is a member of the Executive Committee of the Association of Professors of Cardiology.

    Board Certification and Academic Information

    Academic Departments Internal Medicine -Primary
    Academic Divisions Cardiovascular Medicine

    Education history

    Research Fellow Cardiovascular Disease - Brigham and Women’s Hospital Research Fellow
    Heart Failure and Cardiac Transplantation - Brigham and Women’s Hospital Fellow
    Fellowship Cardiovascular Disease - Brigham and Women’s Hospital Clinical Fellow
    Program in Clinical Effectiveness - Harvard School of Public Health Postgraduate Studies
    Chief Resident Assistant Chief of Service, Osler Medical Service - Johns Hopkins Hospital Chief Resident
    Medicine Preceptor - Johns Hopkins School of Medicine Clerkship
    Internship/Residency Osler Medical Service - Johns Hopkins Hospital Intern/Resident
    Medicine - Duke University School of Medicine M.D.
    Undergraduate Duke University B.A.

    Selected Publications

    Journal Article

    1. Chandra A, Alcala MAD, Claggett B, Desai AS, Fang JC, Heitner JF, Liu J, Pitt B, Solomon SD, Pfeffer MA, Lewis EF (2020). Associations Between Depressive Symptoms and HFpEF-Related Outcomes. JACC Heart Fail, 8(12), 1009-1020. (Read full article)
    2. Zenger B, Zhang M, Lyons A, Bunch TJ, Fang JC, Freedman RA, Navaravong L, Piccini JP, Ranjan R, Spertus JA, Stehlik J, Turner JL, Greene T, Hess R, Steinberg BA (2020). Patient-reported outcomes and subsequent management in atrial fibrillation clinical practice: Results from the Utah mEVAL AF program. J Cardiovasc Electrophysiol, 31(12), 3187-3195. (Read full article)
    3. Teerlink JR, Diaz R, Felker GM, McMurray JJV, Metra M, Solomon SD, Adams KF, Anand I, Arias-Mendoza A, Biering-Srensen T, Bhm M, Bonderman D, Cleland JGF, Corbalan R, Crespo-Leiro MG, Dahlstrm U, Echeverria Correa LE, Fang JC, Filippatos G, Fonseca C, Goncalvesova E, Goudev AR, Howlett JG, Lanfear DE, Lund M, Macdonald P, Mareev V, Momomura SI, OMeara E, Parkhomenko A, Ponikowski P, Ramires FJA, Serpytis P, Sliwa K, Spinar J, Suter TM, Tomcsanyi J, Vandekerckhove H, Vinereanu D, Voors AA, Yilmaz MB, Zannad F, Sharpsten L, Legg JC, Abbasi SA, Varin C, Malik FI, Kurtz CE, GALACTIC-HF Investigators (2020). Omecamtiv mecarbil in chronic heart failure with reduced ejection fraction: GALACTIC-HF baseline characteristics and comparison with contemporary clinical trials. Eur J Heart Fail, 22(11), 2160-2171. (Read full article)
    4. Kalogeropoulos AP, Thankachen J, Butler J, Fang JC (2020). Diuretic and renal effects of spironolactone and heart failure hospitalizations: a TOPCAT Americas analysis. Eur J Heart Fail, 22(9), 1600-1610. (Read full article)
    5. Wilcox JE, Fang JC, Margulies KB, Mann DL (2020). Heart Failure With Recovered Left Ventricular Ejection Fraction: JACC Scientific Expert Panel. J Am Coll Cardiol, 76(6), 719-734. (Read full article)
    6. Taleb I, Wever-Pinzon J, Wang W, Koliopoulou A, Dranow E, Yu T, Yin L, McKellar SH, Stehlik J, Fang JC, Wever-Pinzon O, Selzman CH, Drakos SG (2019). Outcomes of Asian-Americans Implanted With Left Ventricular Assist Devices: An Interagency Registry for Mechanically Assisted Circulatory Support (INTERMACS) Analysis. Heart Lung Circ, 29(8), 1226-1233. (Read full article)
    7. Badolia R, Ramadurai DKA, Abel ED, Ferrin P, Taleb I, Shankar TS, Krokidi AT, Navankasattusas S, McKellar SH, Yin M, Kfoury AG, Wever-Pinzon O, Fang JC, Selzman CH, Chaudhuri D, Rutter J, Drakos SG (2020). The Role of Nonglycolytic Glucose Metabolism in Myocardial Recovery Upon Mechanical Unloading and Circulatory Support in Chronic Heart Failure. Circulation, 142(3), 259-274. (Read full article)
    8. Shah KS, Moslehi JJ, Fang JC (2020). Tissue is the Issue, Even During a Pandemic. Circulation, 142(5), 423-425. (Read full article)
    9. Yin MY, Strege J, Gilbert EM, Stehlik J, McKellar SH, Elmer A, Anderson T, Aljuaid M, Nativi-Nicolau J, Koliopoulou AG, Davis E, Fang JC, Drakos SG, Selzman CH, Wever-Pinzon O (2019). Impact of Shared Care in Remote Areas for Patients With Left Ventricular Assist Devices. JACC Heart Fail, 8(4), 302-312. (Read full article)
    10. Steinberg BA, Turner J, Lyons A, Biber J, Chelu MG, Fang JC, Freedman RA, Han FT, Hardisty B, Marrouche NF, Ranjan R, Shah RU, Spertus JA, Stehlik J, Zenger B, Piccini JP, Hess R (2019). Systematic collection of patient-reported outcomes in atrial fibrillation: feasibility and initial results of the Utah mEVAL AF programme. Europace, 22(3), 368-374. (Read full article)
    11. Vardeny O, Claggett B, Vaduganathan M, Beldhuis I, Rouleau J, OMeara E, Anand IS, Shah SJ, Sweitzer NK, Fang JC, Desai AS, Lewis EF, Pitt B, Pfeffer MA, Solomon SD, TOPCAT Investigators (2019). Influence of Age on Efficacy and Safety of Spironolactone in Heart Failure. JACC Heart Fail, 7(12), 1022-1028. (Read full article)
    12. Welt FGP, Fang JC (2019). Pressure Volume System for Management of Heart Failure and Valvular Heart Disease. Curr Cardiol Rep, 21(12), 153. (Read full article)
    13. Shah KS, Fang JC (2019). Is Heart Failure with Preserved Ejection Fraction a Kidney Disorder? Curr Hypertens Rep, 21(11), 86. (Read full article)
    14. Pepin ME, Drakos S, Ha CM, Tristani-Firouzi M, Selzman CH, Fang JC, Wende AR, Wever-Pinzon O (2019). DNA methylation reprograms cardiac metabolic gene expression in end-stage human heart failure. Am J Physiol Heart Circ Physiol, 317(4), H674-H684. (Read full article)
    15. Desai AS, Solomon SD, Shah AM, Claggett BL, Fang JC, Izzo J, McCague K, Abbas CA, Rocha R, Mitchell GF, EVALUATE-HF Investigators (2019). Effect of Sacubitril-Valsartan vs Enalapril on Aortic Stiffness in Patients With Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial. JAMA, 1-10. (Read full article)
    16. Yin MY, Wever-Pinzon O, Mehra MR, Selzman CH, Toll AE, Cherikh WS, Nativi-Nicolau J, Fang JC, Kfoury AG, Gilbert EM, Kemeyou L, McKellar SH, Koliopoulou A, Vaduganathan M, Drakos SG, Stehlik J (2019). Post-transplant outcome in patients bridged to transplant with temporary mechanical circulatory support devices. J Heart Lung Transplant, 38(8), 858-869. (Read full article)
    17. Minamisawa M, Seidelmann SB, Claggett B, Hegde SM, Shah AM, Desai AS, Lewis EF, Shah SJ, Sweitzer NK, Fang JC, Anand IS, OMeara E, Rouleau JL, Pitt B, Solomon SD (2019). Impact of Malnutrition Using Geriatric Nutritional Risk Index in Heart Failure With Preserved Ejection Fraction. JACC Heart Fail, 7(8), 664-675. (Read full article)
    18. Symons JD, Deeter L, Deeter N, Bonn T, Cho JM, Ferrin P, McCreath L, Diakos NA, Taleb I, Alharethi R, McKellar S, Wever-Pinzon O, Navankasattusas S, Selzman CH, Fang JC, Drakos SG (2019). Effect of Continuous-Flow Left Ventricular Assist Device Support on Coronary Artery Endothelial Function in Ischemic and Nonischemic Cardiomyopathy. Circ Heart Fail, 12(8), e006085. (Read full article)
    19. Hegde SM, Claggett B, Shah AM, Lewis EF, Anand I, Shah SJ, Sweitzer NK, Fang JC, Pitt B, Pfeffer MA, Solomon SD (2017). Physical Activity and Prognosis in the TOPCAT Trial (Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist). Circulation, 136(11), 982-992. (Read full article)
    20. Sundaram V, Chaudhry SP, Reddy YN, Longenecker CT, Fang JC (2015). Emergent cesarean section in the catheterization laboratory for spontaneous coronary artery dissection. Am J Cardiol, 115(12), 1777-8. (Read full article)
    21. Vorovich E, French B, Ky B, Goldberg L, Fang JC, Sweitzer NK, Cappola TP (2014). Biomarker predictors of cardiac hospitalization in chronic heart failure: a recurrent event analysis. J Card Fail, 20(8), 569-76. (Read full article)
    22. Ky B, French B, May Khan A, Plappert T, Wang A, Chirinos JA, Fang JC, Sweitzer NK, Borlaug BA, Kass DA, St John Sutton M, Cappola TP (2013). Ventricular-arterial coupling, remodeling, and prognosis in chronic heart failure. J Am Coll Cardiol, 62(13), 1165-72. (Read full article)
    23. Givertz MM, Teerlink JR, Albert NM, Westlake Canary CA, Collins SP, Colvin-Adams M, Ezekowitz JA, Fang JC, Hernandez AF, Katz SD, Krishnamani R, Stough WG, Walsh MN, Butler J, Carson PE, Dimarco JP, Hershberger RE, Rogers JG, Spertus JA, Stevenson WG, Sweitzer NK, Tang WH, Starling RC (2013). Acute decompensated heart failure: update on new and emerging evidence and directions for future research. J Card Fail, 19(6), 371-89. (Read full article)
    24. OGara PT, Kushner FG, Ascheim DD, Casey DE Jr, Chung MK, de Lemos JA, Ettinger SM, Fang JC, Fesmire FM, Franklin BA, Granger CB, Krumholz HM, Linderbaum JA, Morrow DA, Newby LK, Ornato JP, Ou N, Radford MJ, Tamis-Holland JE, Tommaso CL, Tracy CM, Woo YJ, Zhao DX (2013). 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol, 61(4), 485-510. (Read full article)
    25. OGara PT, Kushner FG, Ascheim DD, Casey DE Jr, Chung MK, de Lemos JA, Ettinger SM, Fang JC, Fesmire FM, Franklin BA, Granger CB, Krumholz HM, Linderbaum JA, Morrow DA, Newby LK, Ornato JP, Ou N, Radford MJ, Tamis-Holland JE, Tommaso CL, Tracy CM, Woo YJ, Zhao DX, Anderson JL, Jacobs AK, Halperin JL, Albert NM, Brindis RG, Creager MA, DeMets D, Guyton RA, Hochman JS, Kovacs RJ, Kushner FG, Ohman EM, Stevenson WG, Yancy CW, American College of Cardiology FoundationAmerican Heart Association Task Force on Practice Guidelines (2013). 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation, 127(4), e362-425. (Read full article)
    26. Morrow DA, Fang JC, Fintel DJ, Granger CB, Katz JN, Kushner FG, Kuvin JT, Lopez-Sendon J, McAreavey D, Nallamothu B, Page RL 2nd, Parrillo JE, Peterson PN, Winkelman C (2012). Evolution of critical care cardiology: transformation of the cardiovascular intensive care unit and the emerging need for new medical staffing and training models: a scientific statement from the American Heart Association. Circulation, 126(11), 1408-28. (Read full article)
    27. Fang JC, DeMarco T, Givertz MM, Borlaug BA, Lewis GD, Rame JE, Gomberg-Maitland M, Murali S, Frantz RP, McGlothlin D, Horn EM, Benza RL (2012). World Health Organization Pulmonary Hypertension group 2: pulmonary hypertension due to left heart disease in the adult--a summary statement from the Pulmonary Hypertension Council of the International Society for Heart and Lung Transplantation. J Heart Lung Transplant, 31(9), 913-33. (Read full article)
    28. Butler J, Ezekowitz JA, Collins SP, Givertz MM, Teerlink JR, Walsh MN, Albert NM, Westlake Canary CA, Carson PE, Colvin-Adams M, Fang JC, Hernandez AF, Hershberger RE, Katz SD, Rogers JG, Spertus JA, Stevenson WG, Sweitzer NK, Tang WH, Stough WG, Starling RC (2012). Update on aldosterone antagonists use in heart failure with reduced left ventricular ejection fraction. Heart Failure Society of America Guidelines Committee. J Card Fail, 18(4), 265-81. (Read full article)
    29. Ky B, French B, Levy WC, Sweitzer NK, Fang JC, Wu AH, Goldberg LR, Jessup M, Cappola TP (2012). Multiple biomarkers for risk prediction in chronic heart failure. Circ Heart Fail, 5(2), 183-90. (Read full article)
    30. Stevenson WG, Hernandez AF, Carson PE, Fang JC, Katz SD, Spertus JA, Sweitzer NK, Tang WH, Albert NM, Butler J, Westlake Canary CA, Collins SP, Colvin-Adams M, Ezekowitz JA, Givertz MM, Hershberger RE, Rogers JG, Teerlink JR, Walsh MN, Stough WG, Starling RC (2012). Indications for cardiac resynchronization therapy: 2011 update from the Heart Failure Society of America Guideline Committee. J Card Fail, 18(2), 94-106. (Read full article)
    31. Stevenson WG, Hernandez AF, Carson PE, Fang JC, Katz SD, Spertus JA, Sweitzer NK, Tang WH, Albert NM, Butler J, Westlake Canary CA, Collins SP, Colvin-Adams M, Ezekowitz JA, Givertz MM, Hershberger RE, Rogers JG, Teerlink JR, Walsh MN, Stough WG, Starling RC (2012). Heart Failure Society of America Guideline Committee.Indications for CRT: 2011 Update from the HFSA Guideline Committee. J Card Fail, 18(2), 94-106.
    32. Sipahi I, Carrigan TP, Rowland DY, Stambler BS, Fang JC (2011). Impact of QRS duration on clinical event reduction with cardiac resynchronization therapy: meta-analysis of randomized controlled trials. Arch Intern Med, 171(16), 1454-62. (Read full article)
    33. Ky B, French B, Ruparel K, Sweitzer NK, Fang JC, Levy WC, Sawyer DB, Cappola TP (2011). The vascular marker soluble fms-like tyrosine kinase 1 is associated with disease severity and adverse outcomes in chronic heart failure. J Am Coll Cardiol, 58(4), 386-94. (Read full article)
    34. Byrne KR, Panagiotakis PH, Hilden K, Thomas KL, Peterson KA, Fang JC (2006). Retrospective analysis of esophageal food impaction: differences in etiology by age and gender. Dig Dis Sci, 52(3), 717-21. (Read full article)

    Book Chapter

    1. Ryan J, Natvi J, Fang JC (2015). Hemodynamics in Heart Failure. In Mann DL, Felker GM (Eds.), Heart Failure: A Companion to Braunwald's Heart Disease (3rd Edtiion). St. Louis: Elsevier.

    Case Report

    1. Chow CH, El-Amm C, Liu W, Pastva S, Sipahi I, Fang JC (2013). Reversal of severe biventricular dysfunction from cardiac hemochromatosis with iron removal. Circ Heart Fail, 6(1), e14-5. (Read full article)

    Editorial

    1. Fang JC, Jones TL (2020). Can a Pulmonary Artery Catheter Improve Outcomes in Cardiogenic Shock? JACC Heart Fail, 8(11), 914-916. (Read full article)
    2. Fang JC (2019). Heart-Failure Therapy - New Drugs but Old Habits? N Engl J Med, 381(21), 2063-2064. (Read full article)
    3. Shah KS, Fang JC (2019). Treating the Cardiorenal Syndrome: A Sledgehammer for a Needle's Work? J Card Fail, 25(11), 935-936. (Read full article)
    4. Ibrahim MM, Fang JC (2019). Magnetic Resonance Imaging of Cardiac Allografts: What's Next? Circ Cardiovasc Imaging, 12(10), e009784. (Read full article)
    5. Ryan JJ, Fang JC (2015). Pulmonary hypertension in heart failure: measurable, but how meaningful? J Heart Lung Transplant, 34(3), 310-1. (Read full article)
    6. Fang JC (2012). Heart failure therapy: what should clinicians believe? JAMA, 308(20), 2144-6. (Read full article)

    Letter

    1. Ramalho SHR, Claggett BL, Sweitzer NK, Fang JC, Shah SJ, Anand IS, Pitt B, Lewis EF, Pfeffer MA, Solomon SD, Shah AM (2019). Impact of pulmonary disease on the prognosis in heart failure with preserved ejection fraction: the TOPCAT trial. [Letter to the editor]. Eur J Heart Fail, 22(3), 557-559. (Read full article)
    2. Myhre PL, Vaduganathan M, Claggett BL, Lam CSP, Desai AS, Anand IS, Sweitzer NK, Fang JC, OMeara E, Shah SJ, Shah AM, Lewis EF, Rouleau J, Pitt B, Solomon SD (2019). Application of the H2 FPEF score to a global clinical trial of patients with heart failure with preserved ejection fraction: the TOPCAT trial. [Letter to the editor]. Eur J Heart Fail, 21(10), 1288-1291. (Read full article)
    3. Taleb I, Koliopoulou AG, Tandar A, McKellar SH, Tonna JE, Nativi-Nicolau J, Alvarez Villela M, Welt F, Stehlik J, Gilbert EM, Wever-Pinzon O, Morshedzadeh JH, Dranow E, Selzman CH, Fang JC, Drakos SG (2019). Shock Team Approach in Refractory Cardiogenic Shock Requiring Short-Term Mechanical Circulatory Support: A Proof of Concept. [Letter to the editor]. Circulation, 140(1), 98-100. (Read full article)

    Video/Film/CD/Web/Podcast

    1. Fang JC, Pinney S (2014). Cardiac Transplantation (webinar) [Web].

  • News & Podcasts

    News

    Podcasts